Prevention of chemotherapy induced ovarian damage

Capsule:
We discuss methods for the prevention of chemotherapy-induced ovarian damage, including agents that act on the PI3K/PTEN/Akt follicle activation pathway, apoptotic pathways, the vascular system, and other potential methods of reducing chemotherapy-induced ovotoxicity.

Authors:
Hadassa Roness, Ph.D., Oren Kashi, M.Sc., Dror Meirow, M.D.

Volume 105, Issue 1, Pages 20-29

Abstract:

Recent advances in our understanding of the mechanisms underlying the impact of cytotoxic drugs on the ovary have opened up new directions for the protection of the ovary from chemotherapy-induced damage. These advances have spurred the investigation of pharmacological agents to prevent ovarian damage at the time of treatment. Prevention of ovarian damage and follicle loss would provide significant advantages over existing fertility preservation techniques. This manuscript reviews new methods for the prevention of chemotherapy-induced ovarian damage, including agents that act on the PI3K/PTEN/Akt follicle activation pathway, apoptotic pathways, the vascular system, and other potential methods of reducing chemotherapy-induced ovotoxicity.

  • This article impressively reviews potential future options to protect ovaries from chemotherapy-induced damage. Unfortunately, as the authors point out, most of the discussed treatments are in “very preliminary stages of study” (except GnRH agonists, with multiple studies showing conflicting results). Is it possible to predict which of the discussed agents will be the first to make it to clinical trials?

Translate »